![]() | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Oral, eye drops |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 20% |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.050.071 |
| Chemical and physical data | |
| Formula | C14H12O3S |
| Molar mass | 260.31 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Suprofen is a nonsteroidal anti-inflammatory drug (NSAID) developed by Janssen Pharmaceutica[1] that was marketed as 1% eye drops under the trade name Profenal.
Uses
Suprofen was originally used as tablet, but oral uses have been discontinued due to renal effects.[2] It was subsequently used exclusively as a topical ophthalmic solution, typically to prevent miosis during and after ophthalmic surgery.[3] This application has been discontinued as well, at least in the US.[4]
References
- ↑ DE 2353357, Janssen PA, Van Daele GH, Boey JM, "Antiphlogistic aroyl-substituted phenylacetic acid derivatives", issued 1974
- ↑ Nies AS (1988). "Renal Effects of Nonsteroidal Anti-Inflammatory Drugs". Basis for Variability of Response to Anti-Rheumatic Drugs. Vol. 24. pp. 95–106. doi:10.1007/978-3-0348-9160-8_9. ISBN 978-3-0348-9931-4. PMID 3142236.
{{cite book}}:|journal=ignored (help) - ↑ "Pharmacy Compounding". Guidance for FDA Staff and Industry Compliance Policy Guides Manual. U.S. Food and Drug Administration. Archived from the original on 1 January 2009.
- ↑ "Suprofen ophthalmic". Drugs.com.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
